CardioCell

CardioCell LLC, founded in 2013 in San Diego, California, is a global biotechnology company dedicated to exploring the therapeutic applications of unique patented ischemia-tolerant mesenchymal stem cells (itMSCs) produced under cGMP conditions. CardioCell holds the global exclusive license from its parent company, Stemedica, to explore therapeutic indications in the cardiovascular field, including conditions such as acute myocardial infarction (AMI), chronic heart failure (CHF), and peripheral artery disease (PAD).